Nine quantum computing firms are about to split $2 billion in federal grants, but the Trump administration is not just handing out checks. In exchange for the capital, the government is taking equity stakes in each recipient. That detail fundamentally changes what this program is. This is not the CHIPS Act as Congress designed it. This is industrial policy as venture capital, and it signals a structural shift in how the federal government will compete in the quantum manufacturing race.
IBM emerges as the clear winner. The company receives $1 billion of the $2 billion pool to fund a new spinout called Anderon, a quantum chip manufacturing company that did not exist two weeks ago. Quantinuum, PsiQuantum, and Atom Computing each land $100 million; Diraq receives $38 million; the remaining four recipients share the rest. The equity stakes vary by recipient, according to the Wall Street Journal report, but the government has not yet disclosed the percentages or voting rights that accompany each position. Congressional oversight or FOIA requests will likely surface those term sheets within weeks, and when they do, the real structure of this bet becomes legible.
Why equity stakes matter: under the traditional CHIPS Act bilateral grant model, the federal government writes a check, the company builds a fab, and that is the end of the government's upside. There is no clawback if the company fails; there is no windfall if it succeeds. The equity structure inverts that. If Anderon becomes a $10 billion company, the government's stake is worth proportionally more. If Quantinuum goes public, the taxpayer position crystallizes. This is a departure so significant that it functionally makes these grants a co-investment rather than a subsidy, and it solves a problem Congress created without knowing it. The Section 48D investment tax credit for advanced manufacturing equipment spending expires at the end of 2026. That is five months away. Rather than extend or restructure that credit (which would require legislative action), the Trump administration has simply pivoted to equity stakes as the incentive mechanism. No vote needed. No sunset date. Just a co-owner position that sits on the cap table alongside venture capital.
The IBM dominance is the real story. Anderon receives half the pool while nine firms split the remainder. That imbalance is not accidental. IBM has fab experience, customer relationships, and institutional credibility that Quantinuum and PsiQuantum do not, both of which are venture-backed and have never manufactured chips at scale. IBM's $1 billion will buy land, equipment, and headcount at a velocity that startup capital cannot match. Within 18 months, Anderon will likely announce a facility location and groundbreaking timeline. Quantinuum will be fundraising to match that pace. The competitive gap widens the moment the checks clear.
What happens next depends on three open questions. First: when does the government disclose equity percentages and board rights? If Washington holds meaningful voting power on Anderon's board, this becomes a quasi-public manufacturing company, with disclosure obligations that private venture-backed startups simply do not face. Second: do other quantum manufacturers file SEC disclosures under pressure to reveal government ownership stakes? Transparency would expose whether PsiQuantum and Atom Computing are now effectively semi-public enterprises with hidden federal ownership. Third: will other advanced manufacturing sectors now expect equity co-investment rather than pure grants? Solar manufacturers, battery producers, rare-earth processors, all will watch how Anderon performs and what the government's equity position yields. If the quantum bet pays off, equity becomes the preferred incentive structure across the industrial base. If Anderon stumbles, Congress will demand answers about why taxpayers are co-investors in a manufacturing company that failed.